Jazz Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Jazz Pharmaceuticals (Palo Alto, CA): 9 reconciled FDA prescription therapies (1.6% 2025 to 2030 cliff risk), $1.24B 2024 CMS Part D & Medicaid spend, and 22 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterPalo Alto, CA
Reconciled FDA Portfolio Therapies9
2025 to 2030 Patent-Cliff Revenue Exposure1.6%
Primary Portfolio LOE Date2029-01-01
2024 CMS Total Public Spend$1.24B
2024 Medicare Part D Spend$490.8M
2024 Medicaid Spend$751.7M
California HCAI SB 17 Filings22 WAC filings (max 23.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.